AcquisitionsThe recent acquisition of Cerevel and its lead asset Emraclidine is positively impacting the outlook for Abbvie.
EarningsStrong Immunology and Oncology performance, with key drugs like Humira, Rinvoq, Skyrizi, and Imbruvica exceeding consensus estimates.
Growth ProspectsThe aging population and increased adoption of advanced drugs will provide further long-term growth.